Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

TRVI

Trevi Therapeutics Inc

Apr 17 • 04:00PM ET

2.58

Dollar change -0.09
Percentage change -3.19	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO SURI IWC AVSC VTWV DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.29	Insider Own	33.43%	Shs Outstand	68.28M	Perf Week	-5.49%
Market Cap	177.92M	Forward P/E	-	EPS next Y	-0.45	Insider Trans	0.00%	Shs Float	45.90M	Perf Month	-20.62%
Income	-29.07M	PEG	-	EPS next Q	-0.09	Inst Own	43.63%	Short Float	2.28%	Perf Quarter	91.11%
Sales	0.00M	P/S	-	EPS this Y	-34.96%	Inst Trans	43.28%	Short Ratio	3.48	Perf Half Y	37.23%
Book/sh	1.21	P/B	2.13	EPS next Y	-14.23%	ROA	-27.37%	Short Interest	1.04M	Perf Year	39.46%
Cash/sh	1.20	P/C	2.14	EPS next 5Y	-	ROE	-30.59%	52W Range	0.97 - 4.00	Perf YTD	92.54%
Dividend Est.	-	P/FCF	-	EPS past 5Y	27.24%	ROI	-34.78%	52W High	-35.50%	Beta	0.94
Dividend TTM	-	Quick Ratio	15.03	Sales past 5Y	0.00%	Gross Margin	-	52W Low	165.98%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	15.03	EPS Y/Y TTM	46.58%	Oper. Margin	0.00%	RSI (14)	36.94	Volatility	9.66% 8.64%
Employees	25	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	7.40
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-40.11%	Payout	-	Rel Volume	0.83	Prev Close	2.66
Sales Surprise	-	EPS Surprise	12.76%	Sales Q/Q	-	Earnings	Mar 20 AMC	Avg Volume	300.08K	Price	2.58
SMA20	-19.37%	SMA50	-8.06%	SMA200	25.17%	Trades		Volume	249,858	Change	-3.19%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-12-23	Initiated	B. Riley Securities	Buy	$6
Nov-22-22	Initiated	SVB Leerink	Outperform	$6
Jun-03-19	Initiated	SVB Leerink	Outperform	$14
Jun-03-19	Initiated	Stifel	Buy	$20
Jun-03-19	Initiated	Needham	Buy	$18
Jun-03-19	Initiated	BMO Capital Markets	Outperform	$15

Apr-09-24 07:30AM	Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference (PR Newswire) -8.13%
Apr-04-24 08:30AM	Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick (Zacks)
07:30AM	Trevi Therapeutics to Participate in Upcoming April Events (PR Newswire)
Apr-02-24 07:30AM	Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team (PR Newswire)
Mar-21-24 10:46AM	Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:53PM	Loading…
Mar-20-24 08:53PM	TRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
05:33PM	Trevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical Trials (GuruFocus.com)
04:05PM	Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates (PR Newswire)
Mar-13-24 04:05PM	Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024 (PR Newswire)
Feb-28-24 07:30AM	Trevi Therapeutics to Participate in Upcoming March Events (PR Newswire) +5.78%
Feb-06-24 07:30AM	Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (PR Newswire)
Jan-17-24 12:00PM	Trevi Therapeutics, Inc. (TRVI) Upgraded to Strong Buy: Here's Why (Zacks)
Jan-04-24 07:30AM	Trevi Therapeutics Provides Business Updates (PR Newswire) +5.34%
Dec-05-23 07:30AM	Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) (PR Newswire)
Nov-30-23 09:35AM	Down -38.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Trevi Therapeutics, Inc. (TRVI) (Zacks)
09:55AM	Loading…
Nov-14-23 09:55AM	Trevi Therapeutics, Inc. (TRVI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks) +6.72%
09:35AM	After Plunging -28.72% in 4 Weeks, Here's Why the Trend Might Reverse for Trevi Therapeutics, Inc. (TRVI) (Zacks)
Nov-12-23 11:13AM	Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:05PM	Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Nov-02-23 07:30AM	Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio for Refractory Chronic Cough (PR Newswire) -5.68%
Nov-01-23 04:05PM	Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023 (PR Newswire)
Oct-13-23 08:30AM	Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio in Prurigo Nodularis (PR Newswire)
Oct-11-23 12:00PM	Trevi Therapeutics, Inc. (TRVI) Upgraded to Buy: Here's What You Should Know (Zacks)
Sep-06-23 07:30AM	Trevi Therapeutics to Participate in Upcoming September Events (PR Newswire)
Aug-12-23 08:30AM	Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-11-23 06:44AM	Q2 2023 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 04:05PM	Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Aug-03-23 04:05PM	Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023 (PR Newswire)
Aug-01-23 07:30AM	Trevi Therapeutics to Participate in Upcoming August Events (PR Newswire)
Jul-06-23 07:30AM	Trevi Therapeutics to Participate in Upcoming July Investor Events (PR Newswire)
10:45AM	Loading…
Jun-04-23 10:45AM	Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) top owners are private equity firms with 35% stake, while 32% is held by hedge funds (Simply Wall St.)
May-30-23 07:30AM	Trevi Therapeutics to Participate in Upcoming June Conferences (PR Newswire) -14.81%
May-22-23 04:05PM	Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence (PR Newswire) -5.00%
May-16-23 11:46AM	Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-12-23 06:38AM	Q1 2023 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -5.67%
May-11-23 04:05PM	Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
May-10-23 08:48AM	Is a Surprise Coming for Trevi Therapeutics (TRVI) This Earnings Season? (Zacks)
May-09-23 07:30AM	Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023 (PR Newswire)
May-04-23 04:05PM	Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023 (PR Newswire)
May-02-23 07:30AM	Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference (PR Newswire)
Apr-27-23 07:30AM	Trevi Therapeutics to Participate in Upcoming May Investor Events (PR Newswire)
Apr-11-23 04:05PM	Trevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-18-23 02:03AM	Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 06:19AM	Q4 2022 Trevi Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-16-23 04:05PM	Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update (PR Newswire)
Mar-09-23 04:05PM	Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023 (PR Newswire) -9.22%
Mar-08-23 07:30AM	Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis (PR Newswire)
Mar-06-23 04:05PM	Trevi Therapeutics to Participate in Upcoming March Conferences (PR Newswire)
Feb-21-23 07:00AM	Presenting on the Emerging Growth Conference on February 22 Register Now (GlobeNewswire) -10.73%
Feb-16-23 07:30AM	Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023 (PR Newswire)
Feb-02-23 07:30AM	Trevi Therapeutics to Present and Participate in Upcoming February Conferences (PR Newswire) +20.17%
Jan-25-23 09:00AM	Trevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clinical Studies for Its Investigational Oral Therapy Haduvio(TM) with The Stock Day Podcast (Newsfile)
Jan-05-23 04:05PM	Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences (PR Newswire) +8.49%
Dec-26-22 08:26AM	Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) stock price dropped 13% last week; private equity firms would not be happy (Simply Wall St.)
Dec-19-22 04:05PM	Trevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference (PR Newswire)
Nov-14-22 04:05PM	Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer (PR Newswire)
Nov-10-22 04:05PM	Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
Nov-08-22 07:30AM	Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference (PR Newswire)
Nov-03-22 04:05PM	Trevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022 (PR Newswire)
Oct-27-22 07:30AM	Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting (PR Newswire)
Sep-30-22 09:40AM	Is AVEO Pharmaceuticals (AVEO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-23-22 01:18AM	/C O R R E C T I O N -- Trevi Therapeutics, Inc./ (PR Newswire) -9.56%
Sep-22-22 04:01PM	Trevi Therapeutics Announces Proposed Public Offering (PR Newswire) -12.24%
Sep-19-22 09:35AM	Trevi Therapeutics Shares Jump After Complete Data From Chronic Cough Trial (Benzinga) -6.13%
07:30AM	Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis (PR Newswire)
Sep-14-22 09:40AM	Is AVEO Pharmaceuticals (AVEO) Outperforming Other Medical Stocks This Year? (Zacks)
Sep-07-22 07:30AM	Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Aug-30-22 04:05PM	Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022 (PR Newswire) -9.50%
Aug-24-22 07:30AM	Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release (PR Newswire)
Aug-22-22 09:30AM	Trevi Therapeutics, Inc. Discusses Commercialization for Its Investigational Therapy, Haduvio, with The Stock Day Podcast (Newsfile)
Aug-11-22 04:05PM	Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update (PR Newswire)
Aug-09-22 07:30AM	Trevi Therapeutics to Present at Upcoming August Conferences (PR Newswire)
Aug-04-22 05:41PM	Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022 (PR Newswire) +5.22%
Jul-21-22 06:45AM	5 Penny Stocks to Buy on the Dip (InvestorPlace) -7.71%
Jul-19-22 09:13AM	Is Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) Shareholder Ownership Skewed Towards Insiders? (Simply Wall St.) +14.33%
Jul-14-22 09:00AM	Traders News Source Senior Editor Mark Roberts Interviews Jennifer Good CEO of Trevi Therapeutics (ACCESSWIRE) -5.03%
Jul-07-22 07:30AM	Trevi Therapeutics to Attend the Twelfth London International Cough Symposium (12th LICS) (PR Newswire)
Jun-30-22 12:53PM	Why Did Needham Lift Price Target For Trevi? (Benzinga) +14.69%
Jun-29-22 08:37AM	Why Trevi Therapeutics Shares Trading Higher Today? (Benzinga) +21.29%
08:36AM	Trevi's stock gains 38% after announcing positive data for skin-disease drug (MarketWatch)
07:30AM	Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio in the Treatment of Prurigo Nodularis (PR Newswire)
Jun-23-22 10:58AM	These 2 Penny Stocks Have Over 300% Upside on the Horizon, Says Oppenheimer (TipRanks) +17.01%
Jun-07-22 07:30AM	Trevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International Convention (PR Newswire)
May-12-22 04:05PM	Trevi Therapeutics Announces First Quarter 2022 Financial Results and Business Update (PR Newswire)
May-05-22 04:05PM	Trevi Therapeutics to Report Q1 2022 Financial Results and Provide a Corporate Update on May 12, 2022 (PR Newswire) -5.66%
May-03-22 07:30AM	Trevi Therapeutics to Present at Upcoming May Meetings (PR Newswire)
Apr-13-22 04:25PM	Are You Looking for a Top Momentum Pick? Why Trevi Therapeutics, Inc. (TRVI) is a Great Choice (Zacks)
Apr-11-22 08:00AM	Trevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference (PR Newswire)
Apr-07-22 08:00AM	Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market (PR Newswire) +56.84%
Apr-05-22 04:25PM	Trevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference (PR Newswire) -8.63%
Mar-23-22 03:25PM	Health Check: How Prudently Does Trevi Therapeutics (NASDAQ:TRVI) Use Debt? (Simply Wall St.)
Mar-22-22 07:30AM	Trevi Therapeutics Hosting Key Opinion Leader Webinar on the Seriousness of Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) (PR Newswire) +14.36%
Mar-17-22 04:05PM	Trevi Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Business Update (PR Newswire)
Mar-15-22 07:30AM	Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough (PR Newswire) +10.61%
Mar-09-22 04:05PM	Trevi Therapeutics to Report Q4 and Year End 2021 Financial Results and Provide a Corporate Update on March 17, 2022 (PR Newswire) +8.18%
Feb-24-22 07:55AM	Why Are Trevi Therapeutics Shares Surging During Premarket Thursday? (Benzinga) +6.52%
07:30AM	Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis (PR Newswire)
Feb-01-22 07:30AM	Trevi Therapeutics Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus in PN (PR Newswire) +9.75%
Jan-25-22 10:00AM	Here's Why Trevi Therapeutics, Inc. (TRVI) Could be Great Choice for a Bottom Fisher (Zacks)
Jan-05-22 07:00AM	Trevi Therapeutics Announces Clinical Trial Updates for Lead Indications (PR Newswire)

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Delfini Lisa	Chief Financial Officer	Oct 11 '23	Option Exercise	0.51	2,292	1,171	36,686	Oct 12 04:00 PM
Delfini Lisa	Chief Financial Officer	Oct 11 '23	Sale	2.02	785	1,586	35,901	Oct 12 04:00 PM
Delfini Lisa	Chief Financial Officer	Sep 11 '23	Option Exercise	0.51	2,291	1,171	35,105	Sep 13 04:06 PM
Delfini Lisa	Chief Financial Officer	Sep 11 '23	Sale	2.20	711	1,564	34,394	Sep 13 04:06 PM
Delfini Lisa	Chief Financial Officer	Aug 11 '23	Option Exercise	0.51	2,292	1,171	33,496	Aug 14 04:00 PM
Delfini Lisa	Chief Financial Officer	Aug 11 '23	Sale	2.36	682	1,610	32,814	Aug 14 04:00 PM
Delfini Lisa	Chief Financial Officer	Jul 11 '23	Option Exercise	0.51	2,292	1,171	31,891	Jul 12 04:29 PM
Delfini Lisa	Chief Financial Officer	Jul 11 '23	Sale	2.34	687	1,608	31,204	Jul 12 04:29 PM
Simon Farrell	Chief Commercial Officer	Jun 20 '23	Option Exercise	0.51	6,250	3,194	45,650	Jun 21 04:00 PM
Delfini Lisa	Chief Financial Officer	Jun 12 '23	Option Exercise	0.51	2,291	1,171	30,209	Jun 14 04:28 PM
Delfini Lisa	Chief Financial Officer	Jun 12 '23	Sale	2.64	610	1,610	29,599	Jun 14 04:28 PM
Delfini Lisa	Chief Financial Officer	May 11 '23	Option Exercise	0.51	2,291	1,171	28,480	May 15 04:00 PM
Delfini Lisa	Chief Financial Officer	May 11 '23	Sale	2.89	562	1,624	27,918	May 15 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TRVI

Trevi Therapeutics Inc

Upgrade your FINVIZ experience